About
Contact & Profiles
A5104651921
Research Areas
- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Asthma and respiratory diseases
Hospital General Universitario De Valencia
2021
Dupilumab is approved as first-line systemic treatment for adults/adolescents with moderate-to-severe atopic dermatitis (AD) in Europe and elsewhere owing to its favourable benefit-risk profile. However, non-steroidal immunosuppressants (NSISS) are often used therapy clinical practice. Impact of prior NSISS on dupilumab's effect vs. control has not been described previously. This study assessed efficacy patients AD, comparing with/without therapy, four phase 3 trials.This post hoc analysis...
10.1007/s13555-021-00558-0
article
EN
cc-by-nc
Dermatology and Therapy
2021-06-18
Coming Soon ...